Aytu BioPharma (AYTU) Institutional Ownership $2.40 -0.04 (-1.64%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.40 0.00 (-0.21%) As of 08/1/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Aytu BioPharma (NASDAQ:AYTU)CurrentInstitutional OwnershipPercentage33.49%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$2.22MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$269.68K Get AYTU Insider Trade Alerts Want to know when executives and insiders are buying or selling Aytu BioPharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data AYTU Institutional Buying and Selling by Quarter Aytu BioPharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/30/2025 FNY Investment Advisers LLC35,921$78K0.0%N/A0.400% 7/15/2025 Kanen Wealth Management LLC573,358$1.25M0.5%N/A6.385% 5/15/2025Armistice Capital LLC57,597$69K0.0%-61.6%0.934% 5/14/2025Stonepine Capital Management LLC463,721$556K0.5%+13.8%7.516% 2/17/2025Stonepine Capital Management LLC407,549$693K0.6%-18.6%6.627% 11/14/2024Stonepine Capital Management LLC500,958$1.18M0.7%+6.0%8.147% 8/15/2024Armistice Capital LLC252,000$736K0.0%N/A4.220% 8/9/2024Dimensional Fund Advisors LP23,551$69K0.0%+54.5%0.394% 8/16/2023Stonepine Capital Management LLC472,369$756K0.3%N/A12.497% 8/11/2023Stonepine Capital Management LLC472,369$756K0.3%N/A12.497% Get the Latest News and Ratings for AYTU and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. 2/7/2023Commonwealth Equity Services LLC309,558$58K0.0%+47.7%9.922% 11/4/2022Prudential Financial Inc.145,550$27K0.0%+257.2%0.233% 11/16/2021Schonfeld Strategic Advisors LLC20,200$58K0.0%-22.8%0.073% 11/12/2021Renaissance Technologies LLC660,604$1.90M0.0%+38.4%2.398% 11/10/2021Creative Planning13,000$37K0.0%N/A0.047% 11/9/2021BlackRock Inc.498,952$1.44M0.0%+3.2%1.811% 10/29/2021Commonwealth Equity Services LLC107,718$310K0.0%+86.4%0.391% 9/17/2021Virtu Financial LLC101,805$510K0.0%N/A0.404% 8/17/2021Millennium Management LLC440,415$2.21M0.0%N/A1.750% 8/16/2021Squarepoint Ops LLC34,487$173K0.0%N/A0.137% 8/16/2021Pinz Capital Management LP21,400$107K0.0%+18.9%0.085% 8/16/2021State Street Corp97,684$489K0.0%-44.9%0.388% 8/16/2021Tibra Equities Europe Ltd60,100$301K0.1%N/A0.239% 8/13/2021Renaissance Technologies LLC477,369$2.39M0.0%+265.7%1.897% 8/13/2021Northern Trust Corp47,061$236K0.0%-77.9%0.187% 8/13/2021Geode Capital Management LLC221,439$1.11M0.0%-38.8%0.880% 8/13/2021Vanguard Group Inc.983,387$4.93M0.0%-5.6%3.907% 8/12/2021Ergoteles LLC75,472$378K0.0%N/A0.300% 8/11/2021Commonwealth Equity Services LLC57,798$289K0.0%+24.0%0.230% 8/11/2021Bank of New York Mellon Corp15,919$80K0.0%-66.0%0.063% 8/11/2021BlackRock Inc.483,448$2.42M0.0%-69.6%1.921% 8/11/2021Deutsche Bank AG20,800$104K0.0%+50.9%0.083% 8/11/2021Susquehanna Fundamental Investments LLC54,819$275K0.0%+33.7%0.218% 8/10/2021WINTON GROUP Ltd57,229$287K0.0%+22.7%0.227% 5/24/2021Principal Financial Group Inc.42,551$323K0.0%+8.2%0.238% 5/21/2021Citadel Advisors LLC24,761$188K0.0%-70.4%0.138% 5/18/2021Citadel Advisors LLC24,761$188K0.0%-70.4%0.138% 5/18/2021California State Teachers Retirement System33,011$251K0.0%+857.1%0.185% 5/17/2021Nuveen Asset Management LLC276,148$2.10M0.0%N/A1.544% 5/17/2021Goldman Sachs Group Inc.77,958$592K0.0%N/A0.436% A new rule goes live in July — and the banks are quietly crushing it (Ad)A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.To help you get started, we're giving away a FREE Wealth Protection Guide that shows you exactly how(Data available from 1/1/2016 forward) AYTU Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of AYTU shares? During the previous two years, the following institutional investors and hedge funds held shares of Aytu BioPharma shares: Kanen Wealth Management LLC ($1.25M), Stonepine Capital Management LLC ($556K), FNY Investment Advisers LLC ($78K), and Armistice Capital LLC ($69K), Dimensional Fund Advisors LP ($69K).Learn more on Aytu BioPharma's institutional investors. What percentage of Aytu BioPharma's stock is owned by institutional investors? 33.49% of Aytu BioPharma's stock is owned by institutional investors. Learn more on AYTU's institutional investor holdings. Which institutional investors have been buying Aytu BioPharma's stock? The following institutional investors have purchased Aytu BioPharma's stock in the last 24 months: Stonepine Capital Management LLC ($1.03M), Kanen Wealth Management LLC ($573.36K), Armistice Capital LLC ($252K), FNY Investment Advisers LLC ($35.92K), and Dimensional Fund Advisors LP ($8.31K). How much institutional buying is happening at Aytu BioPharma? Institutional investors have bought a total of 954,251 shares in the last 24 months. This purchase volume represents approximately $2.22M in transactions. Which of Aytu BioPharma's major shareholders have been selling company stock? The following institutional investors have sold Aytu BioPharma stock in the last 24 months: Stonepine Capital Management LLC ($93.41K), and Armistice Capital LLC ($92.40K). How much institutional selling is happening at Aytu BioPharma? Institutional investors have sold a total of 185,812 shares in the last 24 months. This volume of shares sold represents approximately $269.68K in transactions. Related Companies Invivyd Major Shareholders Adagene Major Shareholders Adaptimmune Therapeutics Major Shareholders Vaxart Major Shareholders Metagenomi Major Shareholders VistaGen Therapeutics Major Shareholders Oramed Pharmaceuticals Major Shareholders Artiva Biotherapeutics Major Shareholders XBiotech Major Shareholders Entera Bio Major Shareholders This page (NASDAQ:AYTU) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
